In a population-based, prospective study of 7,270 men followed for a mean of 11.8 years with serial inflammatory marker measurements, a CRP rise ≥ 1.0 mg/l between two measurements purported a 36% increase in subsequent prostate cancer diagnosis. The gene discussed is CRP; the disease is prostate cancer.